Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  H.U. Group Holdings, Inc.    4544   JP3822000000

H.U. GROUP HOLDINGS, INC.

(4544)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

H U : Announcement Regarding Consolidated Earnings Forecasts

share with twitter share with LinkedIn share with facebook
09/18/2020 | 02:05am EDT

September 18, 2020

To Whom It May Concern

Company Name: H.U. Group Holdings, Inc.

Representative: Shigekazu Takeuchi, President and Group CEO(Securities code: 4544 TSE 1st section)

For inquiries: Naoki Kitamura, Executive Officer and CFOTel: +81-3-5909-3337

Announcement Regarding Consolidated Earnings Forecasts

H.U. Group Holdings, Inc. (hereinafter, the Company) hereby announces the consolidated earnings forecast for the fiscal year ending March 31, 2021, which had not been determined at the time of our announcement of "Consolidated Financial Results for the Fiscal Year Ended March 31, 2020" publicized on May 13, 2020.

1. Earnings forecasts

  1. Consolidated Earnings Forecasts for the six months ending September 30, 2020 (from April 1, 2020 to September 30, 2020)

Operating

Ordinary

Profit attributable

Earnings per

Net sales

to owners of

profit

profit

share

(¥ millions)

parent

(¥ millions)

(¥ millions)

(¥)

(¥ millions)

Previous forecast (A)

Revised forecast (B)

97,500

7,000

undetermined

undetermined

undetermined

Change (B-A)

Change (%)

(Ref.) Six months ended

September 30, 2019

93,480

5,758

4,526

2,544

44.67

(Consolidated)

  1. Consolidated Earnings Forecasts for the fiscal year ending March 31, 2021 (from April 1, 2020 to March 31, 2021)

Operating

Ordinary

Profit (Loss)

Earnings per

Net sales

attributable to

profit

profit

share

(¥ millions)

owners of parent

(¥ millions)

(¥ millions)

(¥)

(¥ millions)

Previous forecast (A)

Revised forecast (B)

200,000

14,000

undetermined

undetermined

undetermined

to 220,000

to 18,500

Change (B-A)

Change (%)

(Ref.) Fiscal year ended

March 31, 2020

188,712

9,939

6,468

(516)

(9.06)

(Consolidated)

- 1 -

(3) Reasons for the announcement

The consolidated financial forecasts for the fiscal year ending March 31, 2021 had not been determined due to difficulties in making reasonable estimates of the COVID-19 pandemic impact. However, as it has become possible for the Company to estimate the forecasts to a certain degree based on the latest available information, the Company hereby announces the above forecasts.

(4) Reasons for the forecasts

Test volume in CLT business, which significantly decreased in April and May due to the COVID-19

pandemic, has recovered to the similar level as the previous year since the month of June. Also, increased number of COVID-19 related tests and sales of the antigen tests (both high-sensitive reagents "Lumipulse SARS-CoV-2 Ag" and rapid test kit "ESPLINE SARS-CoV-2") began to contribute to our earnings, recovering our consolidated business performance. Considering these factors, the Company forecasts consolidated net sales of 97.5 billion yen and consolidated operating profit of 7.0 billion yen for the first six months of the fiscal year ending March 31, 2021.

In and after the third quarter, the Company is not expecting as large decline of test volume in CLT business as it experienced in the months of April to May. However, the outlook of demands for COVID-19 related tests and the aforementioned antigen tests remains unclear to elaborate precise earnings forecasts for the full year. Therefore, the Company has decided to disclose full-year consolidated net sales and consolidated operating profit in a range.

As for the forecasts of ordinary profit and profit attributable to owners of parent, the Company has decided to maintain them as undetermined. This is due to the remaining uncertainties from the impact of COVID-19 pandemic on business performances of the companies accounted for using the equity method in the United States and China. Accordingly, the Company will also maintain the dividend forecast undermined.

  • The earnings forecasts above are based on information available to management at the time of preparation of this document. Actual performance may vary from forecasts.

- 2 -

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Miraca Holdings Inc. published this content on 18 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 September 2020 05:04:02 UTC


share with twitter share with LinkedIn share with facebook
All news about H.U. GROUP HOLDINGS, INC.
09/29MIRACA HOLDINGS INC. : Ex-dividend day for interim dividend
FA
09/18H U : Announcement Regarding Consolidated Earnings Forecasts
PU
06/05Hitachi, Toshiba, Miraca to set up factory for coronavirus antigen tests
RE
04/27Miraca unit seeks approval for Japan's first coronavirus antigen tests
RE
03/30MIRACA HOLDINGS INC. : Ex-dividend day for final dividend
FA
2019MIRACA HOLDINGS INC. : Ex-dividend day for interim dividend
FA
2019MIRACA HOLDINGS INC. : Ex-dividend day for final dividend
FA
2018MIRACA HOLDINGS INC. : Ex-dividend day for interim dividend
FA
2018MIRACA HOLDINGS INC. : Ex-dividend day for final dividend
FA
2017MIRACA HOLDINGS INC. : Ex-dividend day for interim dividend
FA
More news
Financials
Sales 2021 204 B 1 952 M 1 952 M
Net income 2021 6 921 M 66,3 M 66,3 M
Net Debt 2021 47 184 M 452 M 452 M
P/E ratio 2021 22,2x
Yield 2021 3,49%
Capitalization 154 B 1 476 M 1 475 M
EV / Sales 2021 0,99x
EV / Sales 2022 0,96x
Nbr of Employees 5 968
Free-Float 99,1%
Chart H.U. GROUP HOLDINGS, INC.
Duration : Period :
H.U. Group Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends H.U. GROUP HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 3 047,50 JPY
Last Close Price 2 700,00 JPY
Spread / Highest target 24,1%
Spread / Average Target 12,9%
Spread / Lowest Target 3,70%
EPS Revisions
Managers
NameTitle
Shigekazu Takeuchi President & Director
Naoki Kitamura Chief Financial Officer & Director
Hiroaki Kimura Head-Information Technology & Investor Relations
Kazuya Omi Executive Officer, Head-Research & Development
Ryoji Itoh Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
H.U. GROUP HOLDINGS, INC.0.63%1 499
SONIC HEALTHCARE LIMITED24.66%12 232
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.119.72%7 712
NEOGENOMICS, INC.35.73%4 555
DR. LAL PATHLABS LIMITED52.11%2 543
FLEURY S.A.-8.39%1 570